Dysplasia in Gastric Mucosa and its Reporting Problems by Ikonomi, Majlinda et al.
  
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2015 Dec 15; 3(4):551-557.                                                                                                                                                                         551 
 
 
ID Design 2012/DOOEL Skopje 
Open Access Macedonian Journal of Medical Sciences. 2015 Dec 15; 3(4):551-557. 
http://dx.doi.org/10.3889/oamjms.2015.102 
eISSN: 1857-9655 
Basic Science 
  
 
 
Dysplasia in Gastric Mucosa and its Reporting Problems 
 
 
 
 
Majlinda Ikonomi
1
, Blerina Cela
1*
, Dhurata Tarifa
2
 
 
1
Histopathology Laboratory, Oncology Service, Tirana, Albania; 
2
Oncology Service, Chemotherapy, Tirana, Albania 
 
 
 
Citation: Ikonomi M, Cela B, Tarifa D. Dysplasia in 
Gastric Mucosa and its Reporting Problems. OA Maced J 
Med Sci. 2015 Dec 15; 3(4):551-557. 
http://dx.doi.org/10.3889/oamjms.2015.102 
Key words: gastric dysplasia; gastric cancer; 
interobserver variability; dysplasia; neoplasia. 
*
Correspondence: Dr. BLERINA CELA. TIRANE 1000, 
Albania. E-Mail: celablerina@yahoo.com 
Received: 14-Sep-2015; Revised: 29-Oct-2015; 
Accepted: 30-Oct-2015; Online first: 11-Nov-2015 
Copyright: © 2015 Majlinda Ikonomi, Blerina Cela, 
Dhurata Tarifa. This is an open access article distributed 
under the terms of the Creative Commons Attribution 
License, which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original author 
and source are credited. 
Competing Interests: The authors have declared that no 
competing interests exist. 
 
 
 
 
 
 
 
 
 
 
Abstract  
BACKGROUND: The recognition, terminology used and histopathologic evaluation of two essential 
elements in gastric carcinogenesis, atrophy and dysplasia, are characterized by controversy.  
MATERIALS AND METHODS: One hundred fifteen cases, with slides and their histopathologic 
reports from the archive of the Laboratory of Pathology were studied for the diagnostic value, 
reporting of dysplasia, interobserver variability, the relation of dysplastic lesions with inflammation, 
atrophy and metaplasia. After retrospectively studying the histopathologic reports from the archive 
we distributed the cases according to endoscopic and histopathologic diagnosis, together with the 
reexamination of the slides. The comparison of the median values of the numeric variables was 
made with the Mann-Whitney test (non-parametric equivalent of the Student’s “t” test).  
RESULTS: The endoscopic clinical diagnosis were: malignancy/suspicious for malignancy 88 
cases (76%) and non-neoplastic diagnosis (like ulcer or gastritis) 27 cases (24%). From the 
reexamination of the cases it resulted that there is no difference in reporting the malignancy, but 
there is a difference in the cases reported as dysplasia (p = 0.001) and negative for neoplasia (p = 
0.063, borderline).  
CONCLUSION: Clinicians and pathologists can feel directly the discrepancy called “interobserver 
variability” and should be assured that the use of guidelines will cause a lowering of this variability. 
 
 
 
 
 
 
Introduction 
 
In Albania there is an increase in cancer 
incidence the last 20 years and its mortality makes 
10.3% of all deaths and 21% of noncommunicable 
diseases (NCD). The cancer of the gastrointestinal 
tract is the third most common cancer after skin and 
lung [1]. The wide use of endoscopic examination in 
gastroenterology has influenced the management of 
gastric cancer. Remarkable advances have been 
made in Japan, where, nearly 50% of the cases with 
gastric cancer are discovered in an “early” phase, 
which means confined to the mucosa and submucosa. 
In this stage, the disease is treatable and the 5-year 
survival rate can be higher than 90 % [2]. However, if 
we see the global distribution of gastric cancer it is still 
one of the major health problems, despite the 
universal attempts to lower its mortality [3]. Surgery is 
the treatment of choice, but in most of the cases the 
prognosis is not favorable, and the 5-year survival rate 
is lower than 20% in most of the countries, and in 
Albania [4]. It has been studied widely the progressive 
change that go from inflammation to multifocal 
atrophy, intestinal metaplasia, and further to dysplasia 
[5, 6]. However, there is still a controversy in the 
recognition, the terminology used, and histopathologic 
evaluation of its two essential elements: atrophy and 
dysplasia [7-9]. In Albania there are no subspecialties 
in different branches of anatomic pathology and the 
need for a standardized histopathologic report 
became a must after the country opened to the 
international community after the fall of communism.  
Here we present our data in reporting 
dysplasia, its histopathologic features, interobserver 
variability related to it, and the need for the use of 
standardized terminology already proposed for 
reporting gastric lesions.  
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Materials and Method  
 
We have studied retrospectively the 
endoscopic gastric biopsies submitted in the 
Laboratory of Pathologic Anatomy (LAP) in University 
Hospital Centre, ”Mother Theresa”, Tirana, during a 
one year period, in 2011 including the consecutive 
bioptic specimens of 115 cases, with the slides and 
their histopathologic reports, from the archive of the 
LAP. These bioptic specimens were prepared with the 
standard histopathological techniques and stained 
with H-E, PAS and Giemsa. 
The following parameters were evaluated 
from the bioptic materials: the adequacy of the bioptic 
specimen, its diagnostic value, the report of dysplasia, 
the interobserver variability, the relation of dysplastic 
lesions with inflammatory, atrophic and metaplastic 
ones. The retrospective study comprises: a-the review 
of the reports from the Archive with distribution of the 
cases according to endoscopic diagnosis (clinical 
diagnosis), and to the biopsy report b-microscopic 
reexamination. The pathologist has examined the 
slides and made the diagnosis blinded to the results of 
the first examination by other pathologist, but with 
information on patient’s clinical data. During the 
reexamination it is evaluated also the presence of 
active inflammation (PMN), chronic inflammation 
(MN), intestinal metaplasia (M) and atrophy (A).  
The report of dysplasia in the reexamination 
has been made based on Padova classification and 
the report of inflammation, atrophy and intestinal 
metaplasia has been made according to the 
guidelines of the Modified Sydney System (MSS) [6, 
10]. We excluded from the study the lesions that after 
the reexamination were considered not appropriate 
like superficial materials, and those composed entirely 
of necrotic-inflammatory tissue. 
 
Statistical analysis 
The comparison of the median values of the 
numeric variables was made with the Mann-Whitney 
test (non-parametric equivalent of the Student’s “t” 
test). 
To compare the percentages according to the 
different parameter categories we used the test of chi-
square in those cases were the expected value of 
every cell in the table was > 5 (chi-square test for 
independent proportions). To compare the 
percentages according to the different parameter 
categories we used the exact Fisher’s test in the 
cases when the expected value of every cell in the 
table was < 5 (Fisher’s exact test).  
 
 
 
Results 
 
The patients were 66 males and 49 females, 
with a median age of 45 years, ranging from 18-81 
years. The distribution of the cases according to the 
endoscopic clinical diagnosis was: malignancy 
/suspicious for malignancy 88 cases (76%) and the 
nonneoplastic diagnosis (like ulcer or gastritis) 27 
cases (24%).  
After the histopathologic examination of these 
cases, confirmation of carcinoma is done only in 54% 
(48 cases) of the cases suspected and the rest, 46%, 
were referred as dysplasia or negative for neoplasia 
(inflammatory lesions) (Table 1). 
Table 1: Histopathologic  diagnosis 
Adenocarcinoma / Lymphoma Dysplasia Inflammation Not appropriate 
48 (42%) 33 (29%) 29 (25%) 5 (4%) 
  
Considering that 76% of the cases examined 
were materials submitted from macroscopic lesions 
with high clinical suspicion for malignancy, the 
possibility of discovering the dysplastic lesions that 
accompany them can be great. During the distribution 
of the biopsies according to the clinical diagnosis, we 
see that a definitive diagnosis is accomplished only in 
42% of the cases examined and the rest have been 
reported as descriptive diagnosis with the conclusion 
for the repeat of biopsy if clinically suspected. The 
group of the diagnoses with the description of 
dysplasia and inflammation in the histopathological 
report were distributed according to clinical diagnosis. 
From all the cases sent with the clinical diagnosis of 
malignancy, 51% were reported as dysplasia of 
different grades and 49% were reported as without 
neoplastic changes, from 6 cases sent with the clinical 
diagnosis suspicious for malignancy, 50% were 
reported as dysplasia and the rest negative for 
neoplasia (NN) and, from the diagnosis sent as no 
neoplastic lesions, 46% of them displayed dysplasia 
and the rest (54%) were negative for neoplasia (Table 
2). 
Table 2: Comparing the cases of Dysplasia and NN with the 
clinical diagnosis 
 
Clinical Diagnosis 
Histopathological report 
Dysplasia Negative for Neoplasia 
(NN) 
Malignancy (39) 20 (51%) 19 (49%) 
For determination (6) 3 (50%) 3 (50%) 
NonNeoplasia (22) 10 (46%) 12 (54%) 
Total = 67 Total = 33 (49%) Total = 34 (51%) 
 
As we see in Table 2, there is no significant 
difference (p > 0.01) in the data regarding the 
dysplastic lesions in the group strongly suspected for 
malignancy in endoscopy, with the group of clinically 
no neoplastic lesions and those for determination. The 
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same thing is also with the non-neoplastic 
inflammatory lesions.  
Table 3: Reexamination of the cases 
Negative for Neoplasia 
(NN) 
Indefinite for dysplasia   (ID) Dysplasia Not appropriate 
34 (51%) 7 (10%) 22 (33%) 4 (6%) 
 
Taking in consideration the fact that dysplasia 
has the same frequency in the lesions highly 
suspicious for malignancy and those for no neoplastic 
lesions, we raised the question: Are this true 
dysplasia? Maybe, a part of them are atypical 
regenerative changes? What terminology should we 
use to report gastric dysplasia?  
Table 4: Interobserver variability 
 Malignant 
neoplasia 
Dysplasia NN Not appropriate 
First examination 48 33 29 5 
  Dysplasia ID   
Reexamination 48 22 7 34 4 
 
From the reexamination of the cases it 
resulted that there is no difference in reporting the 
malignancy, but there is a difference in the cases 
reported as dysplasia (p = 0.001) and for NN the p 
value is 0.063 (Table 3, Table 4, Fig. 1). 
 
Figure 1: Interobserver variability for dysplastic lesions 
 
When comparing active inflammation, chronic 
inflammation, intestinal metaplasia and atrophy found 
in the histopathological materials of the three 
diagnostic groups (NN, ID and Dysplasia) we see that 
active inflammation (neutrophilic inflammatory 
cells,PMN) and chronic inflammation (mononuclear 
inflammatory cells, MN) are present in all three main 
diagnostic groups and there is no significant 
difference between them. These components are 
more expressed in the group of NN lesions and in the 
group of ID lesions. This expression shows the fact 
that the disease is active in this group of lesions and 
this activity can be the cause of the macroscopic 
changes, like ulcerative lesions, erosions, polypoid 
and exophytic lesions (Table 5, Fig. 2). 
 
 
Table 5: Comparing of the activity, chronic inflammation, 
atrophy and intestinal metaplasia in all 3 groups of lesions 
 NN ID D 
PMN 31 (91%) 7 (100%) 18(82%) 
MN 32 (94%) 6 (86%) 19(86%) 
M 20 (59%) 5(71%) 14(64%) 
A 21 (62%) 4 (57%) 14(64%) 
 
 
Discussion 
 
The process of cancer development 
(cancergenesis) is a process with a lot of steps 
(multistep process) that consists in the consecutive 
genotypic and phenotypic changes [11-13]. The 
recognition of the intermediate phases of this process 
will help in the early identification of cancer and in the 
definition of the risk for malignant transformation of 
these lesions. According to the fact that 76% of the 
cases examined were materials taken from 
macroscopic lesions highly suspicious for neoplasia, 
the possibility of discovering dysplastic lesions that 
accompany them can be considerable, 46% are 
referred in the biopsy report as dysplastic lesions or 
non-neoplastic inflammatory lesions. 
 
Figure 2: Comparison of the activity, chronic inflammation, atrophy 
an intestinal metaplasia in all 3 groups of lesions 
 
This group of lesions reflects either the 
changes of the mucosa adjacent to the macroscopic 
lesions in the cases where it was not possible to 
submit material from the lesion itself, or the changes 
of the macroscopic lesion itself. However, the 
morphological study of this category permits us to 
evaluate its connection with other precancerous 
lesions like dysplasia, intestinal metaplasia, gastric 
atrophy and the presence of inflammation [14]. 
Small endoscopic specimens are not always 
appropriate to reach a definitive diagnosis, which can 
help the clinician in patient management. In our 
material the histopathological reports of a part of 
cases are descriptive and difficult to achieve 
conclusions and also difficult to manage for the 
clinician. This is a known problem in general for 
cytology and small biopsy specimens. Their diagnostic 
productivity is greater with a bigger number of 
specimens submitted, in the form of multiple 
specimens [13]. According to Witzeal et al., [16] the 
diagnostic productivity of the macroscopic lesions of 
the esophagus and stomach in endoscopic biopsies 
was 83%.  
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Figure 3: In the materials from gastric mucosa there is active inflammation (A) with inflammatory cells in lamina propria and 
hyperproliferative gastric crypts (A,B). On the grounds of intestinal metaplasia (B) some of the gastric crypts in the center of the picture,(B) 
are hyperproliferative, with elongated and pseudostratified nuclei ( H-E, 20X). In areas of   atrophy and epithelial metaplasia, (C) the glands 
located deeper in the mucosa have proliferative epithelium, with mitosis even above the basal level, but with a “maturation gradient” towards 
the surface. ( H-E, 20X). In dysplasia (D) there is glandular crowding with some variation in gland size and budding (HE, × 100), elongated 
or oval nuclei with stratification above basal half of the cytoplasm  
 
In our materials there is not a significant 
difference in finding dysplasia in the group that was 
highly suspicious for malignancy with those that were 
not suspicious and the cases for determination. 
According to the literature, from the retrospective 
analysis of surgical specimens for gastric cancer, 
dysplatic epithelium and adenocarcinoma frequently 
accompany each-other, suggesting the role of 
dysplasia as a preceding lesion [17, 18]. What was 
considered as moderate to severe dysplasia, was 
accompanied in 40%-100% of cases with early gastric 
carcinoma, and was found in 50%-80% of advanced 
carcinomas, suggesting a direct role in the 
development of cancer [19]. With the use of fiber-optic 
endoscopy in the late 1960 and early 1970, 
Nakamaura the Nagayo in Japan were the first that 
identified dysplasia as a possible preceding lesion of 
carcinoma and presented soma classification 
algorithms for dysplasia (or atypia as is frequently 
named in Japan) [20, 21]. The reported dates on 
gastric dysplasia vary a lot. The diversity of these data 
is partially because of the differences in the studied 
populations and partially in the different usage of the 
term dysplasia. The origin of the population or a 
population or group with high risk (eg, the patient with 
chronic gastropathy) is important variables during the 
study. The reported dysplasia prevalence in general in 
western countries is from 0. 5% to 3.75%, whether 
values from 9%-20% are reported in areas with high 
risk like Columbia or China [22-24]. The prevalence of 
dysplasia in the patients with chronic atrophic gastritis, 
ulcer, or after gastrectomy, vary from 4-30% up to 
40% in the patients with perinicous anemia [8, 11, 25, 
26]. 
The regenerative process and especially 
reactive and regenerative changes that are noted in 
complete and incomplete intestinal metaplasia 
frequently are like “interpretative pitfalls”. In one 
series, 92% of dysplasia in a population with 20% 
prevalence, were classified as mild dysplasia, what 
makes you think that probably those lesions were not 
dysplasia, but regenerative processes and non true 
neoplastic ones [27, 28].  
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In another study, during the review of the 
cases reported as dysplasia, some pathologist at first 
reported as dysplasia the lesions that after the 
reevaluation were identified as regenerative changes 
[8]. Indefinite for dysplasia is one diagnostic category 
reported during the reexamination of our cases and as 
part of the actual classifications for dysplasia. The 
difference in reporting dysplasia from the first and 
second exam can be explained with the new category 
introduced. This category has similar morphological 
features with dysplasia and is frequently difficult to 
differ from it. In this category are included lesions of 
different groups (Table 6), which have in common the 
reaction or the response of the epithelium to the injury 
as an essential part of the organism homeostasis. In 
some cases, reactive changes have a special aspect. 
Often, this kind of specimen raises the problem of true 
dysplasia or reactive-regenerative changes, which are 
termed before as “regenerative dysplasia” or 
“regenerative atypia” [9, 24]. These regenerative 
changes are seen on the edges of gastric ulcers, on 
the erosions of atrophic gastritis, or lymphocytic 
gastritis, or in the cases of gastropathy from billiar 
reflux or the use of NSAID [29]. The glands show 
irregular architecture, hyperchromatic and stratified 
nuclei, the “atypical” glandular structures are lined by 
epithelial cells without mucus, and prominent nucleoli. 
The mitosis can be frequent. However, the maturation 
towards the surface, “maturation gradient”, (Fig. 3C), 
dense neutrophil infiltrate, and presence of an 
ulcerous lesions, suggest that these are mainly 
reactive-regenerative changes (Fig. 3C). Even in foci 
with intestinal metaplasia, of incomplete type, can be 
seen “hyperplastic” or “hyperproliferative” lesions of 
the glandular crypts deep in the mucosa.  
To eliminate the great variability in the 
histopathological/cytology reporting in general and to 
assure their standardization, in different subspecialties 
of anatomic pathology, there have been created 
reference standards, like the one for PAP test report, 
[31]; for core biopsy for the breast [26], for aspirative 
cytology for the breast or for the thyroid [31], dysplasia 
for Barret’s esophagus and colon dysplasia [32]. The 
difference in reporting dysplasia stands not only in 
including the category of ID, as discussed above, but 
also, its classification in two grades, low grade 
dysplasia and high grade dysplasia, in comparison to 
the previous dysplasia classification in three grades: 
mild, moderate, severe. 
Non standardized diagnostic criteria can 
cause an inappropriate interobserver variability, a 
factor that influences the patient’s care, also the 
evaluation of clinical guidelines [17, 19]. A similar 
classification of dysplasia (with two grades: low and 
severe) is well standardized about the reporting of 
PAP testing or colonic dysplasia [30, 31]. Usually, we 
classify dysplasia in three grades according to 
cytologic and architectural characteristics of the 
epithelial tissue examined [22]. Classifying dysplasia 
in two grades is easier and more reproducible. During 
the grading of dysplasia in three grades, often we 
report an intermediate grade, for example, low to 
moderate or moderate to severe, making it a system 
of three to five grades. The existence of the high and 
low grade alone does not permit us to find 
intermediate terms. In 1984, Ming [20] and an 
international panel recommended that moderate and 
severe dysplasia to be grouped in one category 
because they can not be separated sharply from one-
another and often they co-exist in the lesions. 
In high grade dysplasia the nuclei can be 
found extending to the luminal surface of the cell, 
although in some cases they can be as 2/3 of the 
cellular cytoplasm. The nuclei have irregular shape, 
with prominent, amphophylic nucleoli. In high grade 
dysplasia is included also the so-called “in situ 
carcinoma”, which is a noninvasive lesion, with similar 
cellular changes to carcinoma, but without invasion 
(Fig. 3D). 
In the case of gastric dysplasia, there is still 
not a standardized language, among Albanian 
pathologists, although efforts have been made to 
achieve a consensus in reporting dysplasia, according 
to a pathological and therapeutically view. The 
international actual consensuses are those of Padova 
[32, 33], Hong-Kong [34], and Viena [23]. The 
differentiation of reactive changes like foveolar 
hyperplasia and metaplastic changes are a challenge 
for most of the pathologists [7, 13]. According to a 
series, 51% of cases reported as hyperplastic 
changes, and metaplastic lesions from the 
pathologists specialized in gastropathology, were 
reported first as moderate dysplasia from general 
pathologist [13]. 
The histological diagnosis, especially in our 
country, is considered as full of undisputable “data” 
and the pathologists can be or must be definitive, 
based in the microscopy of their slides. The 
pathologist is considered as one who applies 
“evidence based medicine”. To minimize the 
subjective components (e.g. interobserver variability) 
of the histopathologic diagnosis, different attempts are 
done to assure standardized diagnostic criteria, which 
should be applied in the diagnostic process and 
research of different markers as more objective are 
proposed like lost of Cell polarity protein Lgl2 and 
Claudin-4, mitogen-activated protein kinase kinase 4, 
and stratifin [28]. 
The consequences of non validated 
histopathological classifications can influence the 
management of some patients, consequences that 
aggravate even more when the criteria are not 
sufficient and supposed as accurate [35]. In our 
materials, the variability exists only in the group of 
dysplasia; meanwhile, in the diagnosis of carcinoma, 
there is no disagreement. The pathologist does not 
have doubts also about the nonneoplastic changes 
(Fig. 3A,B). The presence of intestinal metaplasia is 
reported in NN category when it does not display 
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hyperproliferative phenomena, atypia and is not of 
incomplete, colonic type [30].  
According to Plummer M et al., [10], one 
study for histopathological diagnosis of precancerous 
lesions in gastric mucosa had an acceptable 
compatibility for the diagnosis in general, and a 
perfect compatibility for advanced lesions, meanwhile 
the compatibility was low for low grade lesions.  
In conclusion, although Pathological Anatomy 
is considered a very objective discipline and based in 
the “evidence”, it is influenced by a subjective 
parameter that is the Histopathologist himself. 
Clinicians and pathologists can feel directly this 
discrepancy called “interobserver variability”. They 
should be assured that those can be real 
interpretative difficulties in diagnosis of true dysplasia 
and be aware in the same time that the use of 
guidelines will cause a lowering of this variability. 
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